source
- Capsida proposes new monkey testing framework after fatal gene therapy trial for brain diseaseResearchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
- FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimabThe U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…